Compared to original PreserVision AREDS 2 Soft Gel

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Your Ally in Eye Care

We share a goal: To reduce the risk of progression to advanced AMD and its associated vision loss. That’s why we’ve worked with the National Eye Institute (NEI) to develop the only formula recommended by the NEI to help reduce progression in patients with moderate to advanced AMD.

The AREDS Studies

How We Help You Help Your Patients

Our Patented Formula

PreserVision® contains the exact levels of nutrients recommended by the NEI to help reduce the risk of moderate to advanced AMD progression.

20 Years of Clinical Science

Our collaboration with the NEI spanned two decades of AREDS trials.

Samples for Your Patients

Use our order hotline to request PreserVision®
AREDS 2 Formula MiniGel or Chewable samples (while supplies last).

The Science

Placebo-controlled and randomized, the AREDS and AREDS2 clinical trials spanned two decades and demonstrated that a nutrient formula can help moderate to advanced AMD patients lower their risk of progression.

The AREDS Studies

The Supplement

PreserVision® contains the exact levels of nutrients recommended by the NEI to help reduce the risk of moderate to advanced AMD progression.

Our Patented Formula
Top Reasons Why ECPs
Recommend PreserVision®

(We surveyed 200 optometrists and ophthalmologists)

1

Contains the formulation recommended by the NEI to help lower the risk of moderate to advanced AMD progression.1

2

Matches the exact levels of key nutrients recommended by the NEI.

3

No side effects or tolerability issues reported in the AREDS trials.2

  1. Over 5 years, compared to placebo.
  2. Two doses per day, every day.

Helping You Help Your Patients

How many minutes can you give to each AMD patient? Our patient education website and materials can help you offer maximum support.

For Your Patients

Text Size:A−A+